Clinical-stage biotechnology developer of therapeutics for Duchenne muscular dystrophy and other rare diseases, advancing a lead candidate with anti-inflammatory, anti-fibrotic activity that promotes healthy muscle regeneration. Second clinical candidate is a selective androgen receptor modulator designed to build muscle mass and strength.